- Home
- ASBP vs ITOC Comparison
ASBP vs ITOC Comparison
Compare ASBP & ITOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASBP | ITOC |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 7.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ASBP | ITOC |
|---|---|---|
| Price | $5.73 | $0.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 17.9M | 374.9K |
| Earning Date | 04-08-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.25 |
| 52 Week High | $6.39 | $0.65 |
Technical Indicators
Market Signals| Indicator | ASBP | ITOC |
|---|---|---|
| Relative Strength Index (RSI) | 85.43 | 43.52 |
| Support Level | $0.21 | $0.29 |
| Resistance Level | N/A | $0.36 |
| Average True Range (ATR) | 0.32 | 0.04 |
| MACD | 0.67 | -0.00 |
| Stochastic Oscillator | 89.49 | 12.95 |
Price Performance
Historical ComparisonAbout ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
About ITOC iTonic Holdings Ltd Class A Ordinary Shares
iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors.